Scientists have identified a gene that may potentially predict whether prostate cancer will develop into its most lethal form -a finding that could help doctors in the future decide how to treat men with the disease in its early stages (Varambally S et al. Nature 2002; 419: 624 -629). Prostate cancer is the second-deadliest form of cancer among American men, behind lung cancer. In the USA, approximately 189 000 men are diagnosed with the disease each year and metastatic prostate cancer kills more than 30 000 men each year. In their study, University of Michigan Medical School researchers examined tumour cells taken from prostate cancer patients and found 55 genes that were more active in metastatic cells than non-metastatic cells. The polycomb protein enhancer of zeste homolog (EZH2) was overexpressed in hormone-refractory metastatic prostate cancer. Small interfering RNA duplexes targeted against EZH2 reduced the amounts of EZH2 protein present in prostate cancer cells and also inhibited cell proliferation in vitro. Clinically localized prostate cancer cells that expressed higher concentrations of EZH2 showed a poorer prognosis. The authors of the report suggest that dysregulated expression of EZH2 may be involved in the progression of prostate cancer, as well as being a marker that distinguishes indolent prostate cancer from those at risk of lethal progression.
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If a test can be developed, EZH2 protein levels could be used to decide which patients need aggressive treatment, including radiation or surgery. The researchers suggest the prevalence of EZH2 in the tumour cell more accurately predicts a patient's survival than the PSA level, which is the current marker for the disease. A recent study reported that many men over 60 receive unnecessary surgery and other treatments for prostate cancer that is unlikely to spread. Prostate surgery can cause impotence and urinary incontinence.
Increased prostate cancer risk due to breast cancer gene fault A genetic fault that makes women more susceptible to breast and ovarian cancer also raises a man's risk of developing prostate cancer. Dr Ros Eeles of The Institute of Cancer Research presented findings at the first annual meeting of the medical charity Cancer Research UK which indicate that men with an inherited defect in the BRCA 2 gene have a 5 -7-fold increased risk of prostate cancer compared with those without the fault. A European-wide study is planned of 500 men who have four or more close relatives who have developed breast cancer before the age of 60. The aim is to identify a high-risk group of men who can be targeted for screening. It has been revealed that 40% of early-onset, aggressive prostate cancers are linked to inherited factors. The trial will commence early in 2003 and will involve screening men with the BRCA 2 mutation with the PSA test for 5 y. Men with increased PSA levels will be offered biopsy. This trial will be one of the first to use genetic screening to target men in this way. This is clearly of benefit as, in the future, with the increase in pressure on screening programs, it will not be possible to screen every man and a more targeted approach will be needed.
New prostate cancer blood test
Researchers from the Food and Drug Administration and the National Cancer Institute have reported a study on a new blood test for prostate cancer (Petricoin EF et al. J Natl Cancer Inst 2000; 94: 1576 -1578 . The test manufactured by Correlogic Systems Inc., Bethesda, Maryland analyses serum proteomic mass spectra, as it is believed that changes in serum proteomic patterns may be diagnostic of the disease. Sera from 31 men with prostate cancer were compared with sera from 25 men who were cancer free. This allowed a baseline pattern of proteins to be identified that were found only in men with prostate cancer. The proteomic pattern correctly predicted 36 of 38 subsequent patients with prostate cancer, while 177 of 228 patients were correctly diagnosed as having benign conditions. For men with marginally elevated PSA levels (4 -10 ng/ml; n ¼ 137), the specificity was 71%.
It is envisaged that the use of this new test alongside the PSA test will significantly increase the accuracy of diagnosing prostate cancer. Proteomic pattern testing has previously been shown to be of benefit in predicting ovarian cancer. As Peter Levine, the president of Correlogic, pointed out, 'The presence of prostate cancer can be revealed through hidden protein patterns. This is truly the beginning of a revolution in early disease detection.' Alpha 1-adrenoceptor antagonists as radiosensitizers Cuellar et al. (Anticancer Res 2002; 22: 1673 -1679 ) have reported on the potential additive/synergistic apoptotic effect of a 1 -adrenoceptor antagonists with ionizing radiation against human prostate cancer cells in vitro. Androgen-C independent prostate cancer cells can undergo apoptosis in response to non-androgen ablative means such as ionizing radiation. Recent evidence suggests the ability of a-adrenoceptor antagonists, a widely used medical therapy for the treatment of BPH, to induce apoptosis in benign and malignant prostate cells.
Doxazosin and terazosin were used to treat androgenindependent human prostate cancer cells (PC-3) for various periods of time prior to and after exposure to ionizing radiation. Apoptosis induction, cell viability and clonogenic assays were then performed to determine loss of clonogenic survival. The apoptotic morphology of the prostate cancer cells was also studied, as well as the temporal protein expression of the apoptosis regulators bax and caspase-3.
No significant difference in cell death of PC-3 cells was detected when either doxazosin or terazosin was combined with ionizing radiation. Terazosin treatment, however, 24 h prior to, or 24 h post-irradiation resulted in a significant enhancement of radiation-induced loss of clonogenic survival compared with radiation alone. In addition, there was a further significant increase in apoptosis induction when cells were pre-treated with terazosin, compared with treatment with radiation alone. A significant increase in bax protein expression (but not caspase-3) in response to radiation was reported, with no additional effect with either combination treatment.
Cancer survival rates improve
Substantial improvements in long-term survival rates for many types of cancer have been reported in recent decades due to advances in early detection and treatment. However, traditional cohort-based methods of survival analysis are only able to identify this improvement many years after it has occurred. A report by a German epidemiologist, Professor Hermann Brenner (Lancet 2002; 60: 1131 -1135 suggests that this situation can be improved by the use of period analysis. The 1973 -1998 database of the Surveillance, Epidemiology, and End Results (SEER) programme of the US National Cancer Institute was analysed by period analysis. Estimates of 5, 10, 15 and 20 y relative survival rates for all types of cancer were 63, 57, 53 and 51%, respectively. These estimates were 1, 7, 11 and 11% higher, respectively, than corresponding estimates from cohort-based survival analysis. Using period analysis, 20 y relative survival rates for prostate cancer exceeded 80%, an improvement over the last 10 -15 y. Research also indicates that estimated life expectancy has increased for the most frequent types of cancer within the past three decades. Nevertheless, cancer of the oesophagus, liver, pancreas and lung continue to have very poor 20 y relative survival rates of between 2 and 8%.
Effect of vitamin E on prostate cancer cell growth
Vitamin E has been shown to be a chemopreventative agent for prostate cancer in a number of epidemiological studies. A derivative of vitamin E, alpha-tocopheryl sulphate (VES), is able to modulate prostate cancer cell growth. Ni et al. (Biochem Biophys Res Commun 2003; 300: 357 -363 ) report on a study showing that VES causes arrest at the G1 phase of the human prostate cancer cell line, LNCaP. They deduce that the mechanism involves decreased expression of the cell cycle regulatory proteins cyclin D1, D3, E, cdk2 and 4. VES was also shown to reduce cdk4 kinase activity, ribosome phosphorylation and cyclin E mRNA expression. These results suggest that the inhibitory effect of VES is a consequence of its effects on several molecules within the prostate cancer cell cycle regulatory process.
Vitamin D plus docetaxol in advanced prostate cancer
Recent data suggest that the addition of high-dose cacitrol, the active form of vitamin D, to weekly treatment with docetaxel improves the therapeutic response in men with metastatic androgen-independent prostate cancer (Beer et al. J Clin Oncol 2003; 21: 123 -128) . In a phase II in the USA, 37 patients were treated with oral calcitrol (0.5 mg/kg) on day 1 followed by docetaxol (36 mg/m 2 ) on day 2. This was repeated weekly for 6 weeks of an 8 week cycle. Patients maintained a reduced calcium diet and increased oral hydration. The primary end-point was PSA response, defined as a 50% reduction at 4 week follow-up. Of the 37 patients treated, 30 achieved a PSA response and 22 patients had a >75% reduction in PSA. Of the 15 patients with measurable disease, eight had a confirmed partial response. Median time to progression was 11.4 months and median survival was 19.5 months. Overall survival at 1 y was 89%. Treatment-related toxicity was similar to that anticipated for docetaxol alone. It was also noted in a separate study that the pharmacokinetics of each agent were not affected by the combination treatment.
TERE1, a novel gene in prostate cancer regulation
The TERE1 gene maps to chromosome 1p36.11 -1p36.33 between the microsatellite markers D1S2667 and D1S434 and has previously been linked with regulation of bladder cancer growth. McGarvey et al. (Prostate 2003; 54: 144 -155) have examined the expression of the TERE1 transcript and protein in a series of 30 microdissected prostate tumours using semi-quantitative RT-PCR and immunohistochemistry. They report a significant 61% decrease in the TERE1 transcript in prostate carcinoma and a distinct loss of the TERE1 protein in metastatic prostate. Although a loss of heterozygosity at chromosome 1p36 was found in 25% of these prostate tumours, there appeared to be no TERE1 mutations present in tumour samples. Induced TERE1 expression after transduction or transfection of TEREl constructs into two prostate carcinoma (LNCaP and PC-3) cell lines significantly decreased proliferation by up to 80%, with a significant increase in the number of cells in G1. It appears that serum factors, but not dihydrotestosterone regulate the amount of TERE1 protein in the androgen responsive LNCaP cell line. Various growth regulatory genes also appear to be down-regulated or upregulated in TERE1-transduced PC-3 cells. The authors of the report conclude that TEREl might be significant in prostate cancer growth regulation and that down-regulation or absence of TERE1 may be a relevant in the phenotype of advanced disease.
New software package for detection of prostate cancer
A new software package is being launched in the USA by the electronics group Philips to allow better pinpointing of prostate tumours for radiation therapy. The package, called AcQSim Mr, uses magnetic resonance imaging and is expected to benefit not only prostate cancer patients but also those with brain, neck and spinal cancers and soft tissue sarcomas of the extremities. The system will spare more of the normal tissue in the patient from radiation damage and is currently available in the USA.
PC SPES withdrawn
BotanicLab Inc. announced a recall of PC SPES last year due to contamination of certain batches with warfarin (Coumadin) as well as diethylstilbesterol (DES). Confusing test results suggest that some batches contain either or both of these entities and that herbal extracts such as phytocoumarin contained in PC SPES appear to have similar molecular characteristics to DES and warfarin. Any unused product should be returned to the manufacturers immediately. The California State Health Director and the FDA have urged consumers to stop using PC SPES at once and to seek medical advice, particularly if they are currently using any other prescribed medication. It appears that the highest level of warfarin found in one capsule of PC SPES was 0.211 mg. The maximum recommended dose of the agent is six capsules per day, which would be equivalent to 1.27 mg warfarin. This represents 63% of the lowest maintenance dose recommended by the Physician's Desk Reference. The manufacturer is aiming to get new batches of PC SPES to the market as soon as possible.
Changes in molecular forms of PSA during finasteride treatment Espana et al (BJU Int 2002; 90: 672 -677) report on changes in the molecular forms of PSA following finasteride therapy in men with BPH. Measurements were made using sera from 40 men with BPH and a total PSA level of <20 ng/ml before and during treatment with finasteride (30 men) and placebo (10 men). Baseline values were not significantly different between the groups, with mean (SD) total plasma PSA levels of 3.6 (4.3) and 4.8 (5.9) ng/ml reported in the finasteride and placebo groups, respectively. However, finasteride induced a significant reduction in total PSA, free PSA and PSA complexed to alpha1-antichymotrypsin (PSA-alpha1ACT) levels in plasma and serum. Nevertheless, complexed-to-total (c/t) and free-to-total (f/t) PSA ratios remained constant in both groups, both in plasma and serum, during the follow-up.
The authors of the report conclude that the decrease in total PSA after finasteride treatment results from a proportional reduction in its two major molecular forms, free PSA and PSA-alpha1ACT, which explains why the c/t and f/tPSA ratios do not change significantly despite treatment. They go on to suggest that routine analysis of molecular forms of PSA could improve the utility of the change in total PSA associated with finasteride for the early diagnosis of prostate cancer. Any subsequent change in both ratios, particularly an increase in c/tPSA or a decrease in f/tPSA ratio, could be considered an early sign of neoplastic degeneration rather than a therapeutic consequence.
Effect of finasteride on VEGF
Hä ggströ m and co-workers (Scand J Urol Nephrol 2002; 36: 182 -187) report on a study exploring the response to finasteride on the vasculature and the expression of vascular endothelial growth factor (VEGF), a potent regulatory factor of angiogenesis in human prostate tissue. Finasteride has previously been shown to reduce prostate bleeding in patients with BPH. The mechanisms behind this are not known, but it has been suggested that finasteride reduces bleeding by inhibiting angiogenesis in the prostate. Studies in animals have shown that castration rapidly induces involution of the prostate vasculature, and androgen-stimulated prostate growth may be angiogenesis-dependent.
Patients with BPH were randomized to 3 months of treatment with either finasteride (5 mg/day) or placebo before undergoing transurethral resection of the prostate. Prostate tissue VEGF expression, vascular density and serum concentrations of VEGF were measured. Results indicate that patients treated with finasteride (n ¼ 15) had a decrease in prostate tissue VEGF expression compared with placebo (n ¼ 13) treated patients, but that vascular density and serum VEGF levels were unaffected.
A second study prospectively randomizing pretransurethral resection of the prostate patients to finasteride or control was published by Pareek et al. (J Urol 2002; 169: 20 -23) . They found significantly lower microvessel density and VEGF staining in the prostatic suburethral tissue, but not the hyperplastic tissue in patients pre-treated with finasteride. In hormone-sensitive, but not hormoneinsensitive prostate cancer, VEGF has been previously shown to be under androgen regulation in vitro and in vivo (Stewart, J Urol 2001; 165: 688 -693). These results would suggest that the mechanism by which finasteride reduces BPH-associated haematuria is complex and may be related to more than the vascular density of the organ.
Effect of Saw palmetto on DNA content
The actual mechanism whereby Saw palmetto herbal blend (SPHB) exerts its action on the prostate has not been clearly defined, although it is known that it causes contraction of prostate epithelial cells and suppression of dihydrotestosterone levels in men with BPH. Veltri and co-workers (Urology 2002; 60: 617 -622 ) have completed a 6-month study comparing prostatic tissue of men treated with SPHB (n ¼ 20) or placebo (n ¼ 20). Samples were obtained by sextant biopsy before and after treatment. Images were obtained using a DNA imaging system from 200 randomly selected epithelial cell nuclei and 60 nuclear morphometric descriptors (NMDs), e.g. size, shape, DNA content and textural features. It was shown that, at baseline, both treatment groups had similar NMD values. After 6 months on placebo no significant changes were found in NMDs. In contrast, 25 of 60 NMDs in the SPHB group were significantly different from baseline. Changes in DNA chromatin structure and organization of epithelial cells were noted. It was concluded that this study provides evidence for a possible molecular mechanism and therapeutic effect of SHPB.
The triumph project
A retrospective cohort study using the Primary Care Information database within The Netherlands indicates that the incidence rate of lower urinary tract symptoms (LUTS) suggestive of BPH (LUTS/BPH) increases linearly with age, reaching its maximum at 79 years of age (Verhamme K et al. Eur Urol 2002; 42: 323) . The study population comprised 80 774 males (141 035 y of followup) aged 45 y and over who were registered with their general practitioner for at least 6 months prior to the start of follow-up. Overall, 2181 incident and 5605 prevalent cases of LUTS/BPH were identified. A linear increase in LUTS/BPH was observed with three cases per 1000 man-y at age 45 -49 y to a maximum of 38 cases per 1000 man-y at age 75 -79 y. The incident rate remained constant after the age of 80 y. The overall prevalence was 10.3%. The authors concluded that for a symptom-free man aged 46 y, the risk of developing LUTS/BPH over the subsequent 30 y was 45%.
